论文部分内容阅读
目的探讨缬沙坦治疗心血管疾病的临床疗效。方法选取2014年12月—2015年12月赤壁市蒲纺医院收治的心血管疾病患者60例,按照随机数字表法分为对照组与观察组,各30例。对照组给予常规药物(如硝普钠、硝酸脂类等血管扩张剂)治疗,观察组在对照组基础上给予缬沙坦治疗,比较两组患者治疗前后血压[收缩压(SBP)与舒张压(DBP)]控制情况、并发心血管事件发生率、治疗满意度及生活质量[包括PF(生理机能)、生理职能(RP)、躯体疼痛(BP)、一般健康状况(GH)、精力(VT)、社会功能(SF)、情感职能(RE)以及精神健康(MH)]评分。结果治疗前两组患者SBP、DBP及生活质量评分比较,差异无统计学意义(P>0.05);治疗后观察组SBP、DBP及并发心血管事件发生率低于对照组,治疗满意度及PF、RP、BP、GH、VT、SF、RE、MH评分高于对照组,差异有统计学意义(P<0.05)。结论缬沙坦治疗心血管疾病的临床疗效确切,可有效控制患者血压水平,降低并发心血管事件的发生率,且可提高治疗满意度,改善患者生活质量。
Objective To investigate the clinical efficacy of valsartan in the treatment of cardiovascular diseases. Methods Sixty patients with cardiovascular diseases admitted from Dec 2014 to Dec 2015 in Chopin Hospital of Chibi were selected and divided into control group and observation group according to the random number table method, 30 cases in each group. The control group was given routine drugs (such as nitroprusside and nitroglycerin vasodilator), the observation group was given Valsartan on the basis of the control group, and the blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP) control, concurrent cardiovascular events, satisfaction with treatment and quality of life (including PF, physical function, physical pain, general health, ), Social function (SF), emotional function (RE), and mental health (MH) scores. Results There was no significant difference in SBP, DBP and quality of life between the two groups before treatment (P> 0.05). After treatment, the incidence of SBP, DBP and cardiovascular events in the observation group was lower than that in the control group The scores of RP, BP, GH, VT, SF, RE and MH were higher than those of the control group (P <0.05). Conclusion The clinical efficacy of valsartan in the treatment of cardiovascular diseases is accurate, which can effectively control the blood pressure of patients and reduce the incidence of concurrent cardiovascular events, and can improve the satisfaction of treatment and improve the quality of life of patients.